新型生物标志物早期识别与治疗脓毒症的预测经济获益:反事实分析
该研究基于一项非干预性多中心临床试验的结果,分两阶段进行反事实分析:先评估单核细胞分布宽度(MDW)早期识别脓毒症的潜在获益,再通过成本-后果分析估算提前使用抗生素可能带来的经济与临床获益。在349例经急诊入院的成人脓毒症患者中,67%被预测可从MDW结果中获益,抗生素给药时间从标准诊疗的3.98小时降至MDW+标准诊疗的2.07小时。基于此模拟的给药时间缩短,MDW+标准诊疗可能使死亡率降低≤14.2%(27.9% vs 32.5%),平均住院时间缩短1.48天(10.0 vs 11.5天),每例住院节省3,460美元(23,466 vs 26,926美元)。作者结论认为MDW联合标准诊疗估计可改善急诊脓毒症患者的临床与经济结局,但需进一步研究证实这些模型预测。
要点
- 在349例经急诊入院的成人脓毒症患者中,67%被预测可从MDW结果中获益,抗生素给药时间从标准诊疗的3.98小时降至MDW+标准诊疗的2.07小时。
- 基于模拟的给药时间缩短,MDW+标准诊疗可能使死亡率降低≤14.2%(27.9% vs 32.5%),平均住院时间缩短1.48天(10.0 vs 11.5天)。
- 每例住院费用MDW+标准诊疗为23,466美元 vs 标准诊疗26,926美元,每例节省3,460美元。
- 按全国每院每年平均206例脓毒症住院计算,MDW早期识别预测每院每年节省712,783美元。
- 作者结论认为MDW联合标准诊疗估计可改善临床与经济结局,但需进一步研究证实这些模型预测。
适用人群与场景
- 经急诊识别脓毒症并导致住院的成人脓毒症患者。
研究设计与关键结果
- 研究类型为基于非干预性多中心临床试验结果的反事实模型模拟,分两阶段:分析关键注册试验证据以评估MDW早期识别脓毒症的潜在获益,以及成本-后果分析以估算提前使用抗生素可能带来的经济与临床获益。
- 在385例脓毒症患者中,共349例符合纳入标准;67%的患者被预测可从MDW结果中获益。
- 抗生素给药时间从标准诊疗的3.98小时降至MDW+标准诊疗的2.07小时。
- 基于模拟的给药时间缩短,MDW+标准诊疗可能使死亡率降低≤14.2%(27.9% vs 32.5%),平均住院时间缩短1.48天(10.0 vs 11.5天),每例住院节省3,460美元(23,466 vs 26,926美元)。
- 按全国每院每年平均206例脓毒症住院计算,MDW早期识别预测每院每年总费用节省712,783美元。
证据类型、等级与局限
- 证据类型为基于非干预性多中心临床试验结果的模型模拟(反事实分析)。
- 局限:作者指出需进一步研究证实这些模型预测。
对床旁实践的改变
- 作者结论认为,使用MDW联合当前标准诊疗改善急诊脓毒症的早期识别,估计可改善脓毒症患者的临床与经济结局。
- 作者指出需进一步研究证实这些模型预测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To estimate the potential clinical and health economic value of earlier sepsis identification in the emergency department using a novel diagnostic marker, monocyte distribution width.
DESIGN: The analysis was conducted in two phases: 1) an analysis of the pivotal registration trial evidence to estimate the potential benefit of monocyte distribution width for early sepsis identification and (2) a cost-consequence analysis to estimate the potential economic and clinical benefits that could have resulted from earlier administration of antibiotics for those patients.
SETTING: Sepsis identified in the emergency department which led to inpatient hospitalizations.
PATIENTS: Adult sepsis patients admitted through the emergency department.
INTERVENTIONS: None. This was a model simulation of clinical and economic outcomes of monocyte distribution width based on results from a noninterventional, multicenter clinical trial.
MEASUREMENTS AND MAIN RESULTS: Among the 385 patients with sepsis, a total of 349 were eligible for inclusion. Sixty-seven percent of patients were predicted to benefit from monocyte distribution width results, resulting in an estimated mean reduction in time to antibiotics administration from 3.98 hours using standard of care to 2.07 hours using monocyte distribution width + standard of care. Based on this simulated reduction in time to antibiotics, monocyte distribution width + standard of care could have resulted in a less than or equal to 14.2% reduction (27.9% vs 32.5%) in mortality, a mean reduction of 1.48 days (10.0 vs 11.5 d) in length of stay, and $3,460 ($23,466 vs $26,926) savings per hospitalization. At the hospital level, based on an established national mean of 206 sepsis hospitalizations per hospital per year, earlier identification with monocyte distribution width is predicted to result in a total of $712,783 in annual cost savings per hospital.
CONCLUSIONS: Improved early identification of sepsis using monocyte distribution width along with current standard of care is estimated to improve both clinical and economic outcomes of sepsis patients presenting in the emergency department. Further research is warranted to confirm these model projections.
参考来源
- Paoli CJ, Reynolds MA, Coles C, et al. Predicted Economic Benefits of a Novel Biomarker for Earlier Sepsis Identification and Treatment: A Counterfactual Analysis. Crit Care Explor. 2019. PMID: 32166270. doi:10.1097/CCE.0000000000000029
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。